Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoTAG-1 with Paclitaxel and Gemcitabine in Visceral Metastatic TNBC
NCT03002103Phase 3Suspended
- Sponsor
- SynCore Biotechnology
- Start
- Nov 2016
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of EndoTAG-1 in triple-negative breast cancer (TNBC), sponsored by SynCore Biotechnology. Started Nov 2016; status: suspended.
02
Drugs
EndoTAG-1
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03002103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002103.